FLT1 and hepatocellular carcinoma: A recent analysis of the EVOLVE-1 trial investigating everolimus in HCC patients with tumor progression on sorafenib found that the angiogenesis markers vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 were associated with decreased survival21.